ISRIB is an unapproved laboratory compound, sold as a research chemical, that releases a cellular brake on protein production and is used unsupervised in the hope of restoring lost memory. In rodents it reversed memory loss from ageing and head injury and protected the cells that insulate nerve fibres. Every finding comes from animals or cultured cells; no person has taken it in a registered trial. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 10–26 U/L | Detects liver injury from a compound with unpublished human clearance |
| AST | 10–26 U/L | Confirms and localises any ALT rise |
| Lipase | 10–60 U/L | Screens for pancreatic irritation, the toxicity that ended PERK-inhibitor development |
| Fasting glucose | 75–86 mg/dL | Stress-pathway signalling governs glucose handling and transporter expression |
| HbA1c | 4.9–5.3% | Captures glucose drift that a single fasting value misses |
| hs-CRP | <0.5 mg/L | Tracks the inflammatory tone this pathway both responds to and drives |
| eGFR | >90 mL/min/1.73 m² | Kidney clearance matters when elimination routes are unpublished |
| Anti-Müllerian hormone | Above the 50th centile for age; any fall over 12 months is the signal | Detects depletion of the dormant ovarian follicle pool |
| Corrected QT interval | <440 ms in men, <450 ms in women | Screens for the cardiac effect that ended the closest analogue's development |
| Cognitive battery score | No established target; track change against the individual's own two baseline sessions | Measures the claimed benefit rather than a proxy for it |
Cadence: Full baseline panel before any exposure, with a repeatable cognitive battery administered twice; electrocardiogram plus liver and pancreatic enzymes at two weeks and four weeks; full panel at three months and every three to six months during continued use; anti-Müllerian hormone repeated at six months.